The Role of Moringa oleifera- Ifalmin® Formulation in Regulation of B220+IgM+ and B220+IgG+ in Diabetic Mice

Authors

  • Wahyu Isnia Adharini Department of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia http://orcid.org/0000-0001-6023-400X
  • Ruri Vivian Nilamsari Department of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia
  • Noviana Dwi Lestari Department of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia
  • Nashi Widodo Department of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia
  • Muhaimin Rifa'i Department of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia

DOI:

https://doi.org/10.21776/ub.jels.2019.010.01.08

Keywords:

diabetes mellitus, Ifalmin®, immunoglobulin, immunomodulator, Moringa oleifera

Abstract

It has been known that the immunoglobulin levels were altered in diabetes mellitus (DM) conditions. This study aimed to evaluate the levels of immunoglobulins in DM mice after the administration of Moringa oleifera-Ifalmin® formulation (MI). Streptozotocin, at a dose of 145 mg.kg-1, was injected intraperitoneally to experimental mice to obtain diabetic mice. The groups were divided into normal mice, diabetic mice without treatment, diabetic mice with metformin treatment (307.5 mg.kg-1 BW), and diabetic mice with MI treatment at dose 1 (M:I= 800 mg.kg-1 BW: 800 mg.kg-1 BW), dose 2 (M:I= 615 mg.kg-1 BW: 615 mg.kg-1 BW), and dose 3 (M:I= 800 mg.kg-1 BW: 615 mg.kg-1 BW). Mice were orally treated by MI for 14 days. Subsequently, the levels of immunoglobulin IgM and IgG were evaluated using flow cytometry analysis. IgM and IgG levels were significantly lower in the DM group than the normal group. These results indicated that DM altered immunoglobulin levels. MI treatment for 14 days significantly increased the number of IgM and IgG at the level equivalent to the normal group and significantly different as compared to the DM group. Based on the results, MI can be used as an immunomodulatory agent in humoral immunity through the precise regulation of IgM and IgG.

Downloads

Published

2020-06-30

Issue

Vol. 10 No. 1 (2020)

Section

Articles

License

Copyright (c) 2020 The Journal of Experimental Life Science

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Most read articles by the same author(s)

1 2 3 > >>